NCT03598595View on ClinicalTrials.gov

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 28, 2019

Primary Completion Date

November 13, 2025

Study Completion Date

November 13, 2025

Conditions

Recurrent OsteosarcomaRefractory Osteosarcoma

Interventions

DRUG

Docetaxel

Given IV

DRUG

Gemcitabine

Given IV

DRUG

Hydroxychloroquine

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03598595 - Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma | Biotech Hunter | Biotech Hunter